Shorter TB course could be Game-Changer for HIV patients

NCT ID NCT07608172

Not yet recruiting Disease control Sponsor: Shanghai Public Health Clinical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a shorter, 5-month combination of TB drugs works as well as the standard 6-month treatment for people with both HIV and drug-susceptible tuberculosis. It involves 148 participants with very weak immune systems (CD4 count under 100). The goal is to see if the shorter regimen can effectively treat TB while reducing side effects and treatment burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isoniazid, rifapentine, moxifloxacin, pyrazinamide
What this could lead to: If successful, this could offer a shorter, more convenient treatment option for tuberculosis in people with advanced HIV, potentially improving adherence and outcomes.
What could go wrong: This is a relatively small, early-stage validation study. The shorter regimen may not be as effective or safe as the standard longer course, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS TUBERCULOSIS IN HIV-INFECTED INDIVIDUALS

More trials for these conditions

Other studies related to the condition(s) this trial covers.